RICHLAND, Wash., July 6, 2016 /PRNewswire/ -- IsoRay Inc.
(NYSE MKT:ISR), a medical technology company and innovator in seed
brachytherapy and medical radioisotope applications for the
treatment of prostate, brain, lung, head and neck and gynecological
cancers, today announced Jonathan Feddock
M.D., Assistant Professor of Radiation Medicine,
University of Kentucky College of
Medicine, Lexington, Kentucky,
discussed two presentations of gynecologic cancer patients who
underwent treatment with permanent implantation of radiation
therapy sources containing Cesium-131.
Dr. Feddock's first presentation, titled: "Permanent
Interstitial Re-Irradiation with Cesium-131: A Highly Successful
Second Chance for Cure in Recurrent Pelvic Malignancies," described
26 implants which were performed in 21 women who had
experienced recurrent cancers of the uterus, cervix or
vagina. These women had previously been treated with surgery
and/or radiation. Historically, they would have been offered
radical surgery with surgical removal of all pelvic organs.
Of the 26 implants, 21 cancer sites remained visually free of
cancer at a median of 14 months following Cesium-131 implantation,
resulting in a local control rate of 80.7%. Local control in
these cases was confirmed clinically.
Dr. Feddock commented: "These women were facing very radical
surgery to address their recurrent cancers and it turned out that
Cesium-131 therapy offered a much better solution for them.
This is the first study utilizing Cesium-131 therapy for these
gynecologic cancers and we have followed these women closely in
order to evaluate the effectiveness of this treatment. We are
very pleased with the results."
During his second presentation, titled: "Outpatient Interstitial
Implants--Integrating Cesium-131 Permanent Interstitial
Brachytherapy into Definitive Treatment for Gynecologic
Malignancies," Dr. Feddock reported on a series of 22 women with
pelvic cancer who underwent Cesium-131 implantation along with
other forms of radiation therapy. The pelvic cancers in these
patients were recently diagnosed and the patients had not yet
undergone treatment. All these cancers were successfully controlled
at a median follow-up of 16 months. Side effects were minor
and all Cesium-131 treatments were performed as outpatient
procedures.
Dr. Feddock stated: "The field of radiation oncology has long
appreciated getting a high radiation dose to cancer. This
fact is especially true for cancers that are bulky or have other
features that put them at a higher risk of being left behind after
surgery. By implanting Cesium-131 directly into these cancers
we can boost the radiation dose in a way that results in local
control with minimal side effects. The fact that we can
perform this treatment without hospitalization and with local
anesthetic gives these women a very convenient treatment that is
highly successful."
Tom LaVoy, CEO of IsoRay, Inc.,
stated, "We are encouraged by Dr. Feddock's research in women's
cancers as Cesium-131 may provide effective treatments for women
whose only alternative is highly invasive, life changing surgery.
We look forward to Dr. Feddock's ongoing research."
About IsoRay®
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is
the sole producer of Cesium-131 brachytherapy seeds, which are
expanding brachytherapy options throughout the body. Learn more
about this innovative Richland,
Washington Company and explore the many benefits and uses of
Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray.
Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future
expectations, including: the advantages of our products and their
delivery systems, whether results of any future treatments of
women's cancers with Cesium-131 will produce similar results as
these initial studies, and all other statements in this release,
other than historical facts, are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 ("PSLRA"). This statement is included for the express
purpose of availing IsoRay, Inc. of the protections of the safe
harbor provisions of the PSLRA. It is important to note that actual
results and ultimate corporate actions could differ materially from
those in such forward-looking statements based on such factors as
physician acceptance, training and use of our products, our ability
to successfully manufacture, market and sell our products, our
ability to manufacture our products in sufficient quantities to
meet demand within required delivery time periods while meeting our
quality control standards, our ability to enforce our intellectual
property rights, whether additional studies are released and
support the conclusions of past studies, whether ongoing patient
results with our products are favorable and in line with the
conclusions of clinical studies and initial patient results,
patient results achieved when our products are used for the
treatment of cancers and malignant diseases, successful completion
of future research and development activities, whether we, our
distributors and our customers will successfully obtain and
maintain all required regulatory approvals and licenses to market,
sell and use our products in its various forms, continued
compliance with ISO standards as audited by BSI, the success of our
sales and marketing efforts, changes in reimbursement rates,
changes in laws and regulations applicable to our products, and
other risks detailed from time to time in IsoRay's reports filed
with the SEC. Unless required to do so by law, the Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20160301/339505LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/womens-cancer-and-cesium-131-treatments--topic-of-two-presentations-at-the-2016-annual-meeting-of-the-american-brachytherapy-society-and-world-congress-of-brachytherapy-300294475.html
SOURCE IsoRay, Inc.